Upper airway resistance syndrome Respiratory Upper airway resistance syndrome
Conditions
Interventions
Following baseline assessment, participants will be randomised to the experimental condition: therapeutic CPAP (n=10) or sham CPAP (n=10). A permuted blocking procedure will be used for the randomisat
Sponsors
Respironics, Inc (USA)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Physician-confirmed diagnosis of UARS 2. Aged between 21 years or over and 65 years or under 3. Able to speak and read English 4. Ability to tolerate only one caffeinated beverage in the morning
Exclusion criteria
Exclusion criteria: 1. Currently taking an opiate, benzodiazepine, sedative, hypnotic, stimulant, or sleeping medication 2. Currently being treated with a lipid lowering or Blood Pressure (BP) medication 3. Diagnosis and/or treatment for sleep apnea, narcolepsy, or periodic limb movement disorder 4. Diagnosis of diabetes, coronary artery disease, Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), stroke, or seizures 5. Body Mass Index (BMI) over 32 (no lower limit) 6. Evidence of overt alcohol or other substance abuse 7. History of allergy to lidocaine or similar local anesthestics 8. Presence of an extreme gag reflex 9. Difficulty breathing through nose 10. Smoking 11. Waking after 10:00 a.m. and going to bed after 12:00 a.m
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Fatigue 2. Daytime sleepiness 3. Sleep quality | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Pain 2. Headache 3. Gastrointestinal discomfort 4. Metabolic risk factors 5. Hyperarousal | — |
Countries
United States of America
Outcome results
None listed